Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan (CUARTET)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04601441 |
Recruitment Status :
Recruiting
First Posted : October 23, 2020
Last Update Posted : December 8, 2020
|
Sponsor:
Kindai University
Collaborator:
Janssen Pharmaceutical K.K.
Information provided by (Responsible Party):
Hirotsugu Uemura, Kindai University
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | October 12, 2020 | ||||
First Posted Date ICMJE | October 23, 2020 | ||||
Last Update Posted Date | December 8, 2020 | ||||
Actual Study Start Date ICMJE | November 6, 2020 | ||||
Estimated Primary Completion Date | March 31, 2025 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Changes in genomic alterations of 73 PC driver genes between pre- and posttreatment of apalutamide. [ Time Frame: Three years or more, 4.5 years or less ] Seventy-three PC driver genes from ctDNA including ARID1A, HSD3B1, MDM4, AKT3, MSH2, MSH6, ERCC3, NFE2L2, IDH1, FANCD2, MLH1, CTNNB1, FOXP1, RYBP, PIK3CB, ATR, PIK3CA, FBXW7, PIK3R1, CHD1, APC, FANCE, CDK6, MET, BRAF, CUL1, KMT2C, NKX3-1, CLU, NCOA2, MYC, CDKN2A, FANCG, FANCC, PTEN, FANCF, CCND1, ATM, ZBTB16, CDKN1B, KRAS, KMT2D, CDK4, MDM2, BRCA2, RB1, ERCC5, FOXA1, RAD51B, AKT1, IDH2, ERCC4, ZFHX3, FANCA, TP53, CDK12, BRCA1, SPOP, RNF43, RAD51C, AKT2, ERCC2, ERCC1, ASXL1, GNAS, RUNX1, ERG, TMPRSS2, KDM6A, AR, MED12, SMARCA1, and PALB2.
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan | ||||
Official Title ICMJE | Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan | ||||
Brief Summary | To evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment | ||||
Detailed Description | This clinical study is an open-label, multicenter, interventional, Phase 4 study to evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment in patients with mCSPC. A total of 100 participants to be treated by apalutamide will be registered in this study. All participants will undergo blood collection for ctDNA, single-nucleotide polymorphisms (SNPs), and human-leukocyte antigen (HLA) typing at pre- and posttreatment of apalutamide. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 4 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Screening |
||||
Condition ICMJE | Metastatic Castration-sensitive Prostate Cancer | ||||
Intervention ICMJE | Drug: Apalutamide
Apalutamide 240 mg administered orally once a day as four 60 mg tablets
|
||||
Study Arms ICMJE | Apalutamide
Apalutamide 240 mg administered orally once a day as four 60 mg tablets
Intervention: Drug: Apalutamide
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
100 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | March 31, 2025 | ||||
Estimated Primary Completion Date | March 31, 2025 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 20 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | Japan | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT04601441 | ||||
Other Study ID Numbers ICMJE | 56021927PCR4013 jRCTs071200040 ( Registry Identifier: Japan Registry of Clinical Trial (jRCT) ) 56021927PCR4013 ( Other Grant/Funding Number: Janssen Pharmaceutical K.K. ) |
||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Hirotsugu Uemura, Kindai University | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Kindai University | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Janssen Pharmaceutical K.K. | ||||
Investigators ICMJE |
|
||||
PRS Account | Kindai University | ||||
Verification Date | December 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |